Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Etilamfetamine
- Development stage
- Discontinued
- Modality
- Small Molecules
- Administration
- Oral, Intranasal, Inhalation, Intravenous
01
Overview
Etilamfetamine is a synthetic stimulant drug of the phenethylamine and amphetamine chemical classes. It is structurally related to amphetamine and methamphetamine but contains an ethyl group instead of a methyl group on the nitrogen atom. Etilamfetamine acts as a central nervous system stimulant by promoting the release of monoamines such as dopamine and norepinephrine from presynaptic nerve terminals. It was previously used in some countries for indications such as depression and narcolepsy but has largely been discontinued due to concerns about abuse potential and side effects.
- Brand names
- AponeuronAdaptonTimetan
- Other names
- N-ethylamphetamine1-ethylamino-2-phenylpropaneethylamphetamine
02
Targets
DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on Etilamfetamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Etilamfetamine.